| Name | Title | Contact Details |
|---|
Starkey Hearing Technologies is a privately held, global hearing technology company headquartered in Eden Prairie, Minn. We are recognized for our innovative design, development and distribution of comprehensive digital hearing systems. We develop products using an evidence-based design approach, meaning that rigorous testing takes place to prove the benefits of a new technology or algorithm before a hearing aid is ever fit on a patient. Every Starkey Hearing Technologies employee is committed to helping people on their journey to better hearing every day. Starkey Hearing Technologies operates 21 facilities and conducts business in more than 100 markets worldwide. We develop, manufacture and distribute hearing aids via three distinct brands - Audibel, NuEar and our original brand, Starkey.
Viaflo is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
DiaMed is a Canton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biolinq is a startup that has developed a proprietary wearable biosensor platform that is capable of measuring blood level information, without the need to draw blood.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.